Name: Drug Targets in Cellular Processes of Cancer: From Nonclinical to Preclinical Models (en Inglés)
SKU: 59382649
Price: 2054.26 MXN
Availability: InStock
Author: Tuli, Hardeep Singh
ISBN: 9789811575853

portada Drug Targets in Cellular Processes of Cancer: From Nonclinical to Preclinical Models (en Inglés)

Drug Targets in Cellular Processes of Cancer: From Nonclinical to Preclinical Models (en Inglés)

Formato

Libro Físico

Editorial

Springer

Autor

Tuli, Hardeep Singh

Idioma

Inglés

N° páginas

228

Encuadernación

Tapa Dura

Dimensiones

23.9x19.6x1.3 cm

Peso

0.45 kg.

ISBN13

9789811575853

Categorías

Oncología
Inmunología
Biología molecular

Drug Targets in Cellular Processes of Cancer: From Nonclinical to Preclinical Models (en Inglés)

Tuli, Hardeep Singh (Autor) · Springer · Tapa Dura

Libro Nuevo Importado

Envío: 17 a 22 días háb.

$ 3,735.03$ 2,054.26

-45%

Costos de importación incluídos en el precio ✅

Libro Nuevo

Quedan más de 100 unidades

$ 2,054.26

¡Envío Gratis! Llega entre el 19 Nov y el 27 Nov a CUAUHTÉMOC, Ciudad de México. Seleccionar ubicación

Agregar a lista de deseos

Reseña del libro "Drug Targets in Cellular Processes of Cancer: From Nonclinical to Preclinical Models (en Inglés)"

This book explores potential cellular drug targets for cancer therapy. The first couple of chapters describe conventional treatment (radiotherapy, chemotherapy, and immunotherapy) & detection (biosensors) strategies for cancer. In contrast, the subsequent chapters address the role of cyclin-dependent kinases and cell cycle regulatory proteins in the growth of cancer cells and their potential as target for cancer treatment. The book then discusses the regulation of various pro-apoptotic and anti-apoptotic proteins via chemotherapeutic drugs. In addition, it examines the molecular mechanisms that are critical for mediating autophagic cell death in cancer cells. It subsequently reviews the role of reactive oxygen (ROS) species during carcinogenesis and during chemotherapy, and the potential of anti-inflammatory routes for the development of new therapeutic modulators. Lastly, it describes therapeutic strategies that target the tumor microenvironment and various angiogenic pathways for the treatment of cancer and to develop personalized medicine. Given its scope, the book is valuable resource for oncologists, cancer researchers, clinicians, and pharmaceutical industry personnel.